AtriCure, Inc. (ATRC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago.
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call.
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago.
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
